The EU’s General Pharmaceutical Legislation amendment proposal, which was published on 26 April 2023 (“the Proposal”), is introducing new measures to regulate decentralized manufacturing, which is increasingly used for certain categories of medicinal products. In particular, the Proposal introduces new obligations for manufacturers and for national competent authorities overseeing decentralized sites. In this blog
More Posts
EU Pharma Legislation Review Series: Supply Security and Shortages Control
EU Pharma Legislation Review Series: Bolar Exemption under Patent Rights
EU Pharma Legislation Review Series: Regulatory Data Protection
EU Talking Life Sciences Audiocast: Episode 4 – EU and UK Pharmaceutical Regulation of Tax Structures and Financial Flows – Implications for Global Supply Chains
EU Talking Life Sciences Audiocast: Episode 4 – EU and UK Pharmaceutical Regulation of Tax Structures and Financial Flows – Implications for Global Supply Chains
Legislative Proposals for Clinical Trials Aim to Streamline, Simplify and Stimulate UK-based Innovation
UK PMCPA Publishes First Ever Guidance to Pharmaceutical Companies about Social Media
IFPMA and EFPIA Publish New Joint Guidance Note on Social Media and Digital Channels
EMA Publishes Guidance on Clinical Trial Conduct During COVID-19 Pandemic
Connect: http://www.cov.com/rblaney/
Subscribe: Subscribe via RSS